| Abstract |
[Abstract] Objective To study the efficacy of agometatin in the treatment of perimenopausal syndrome complicated with anxiety and depression. Methods A total of 100 patients with perimenopausal syndrome complicated with anxiety and depression in the obstetrics and gynecology department of our hospital from November 2018 to December 2021 were selected as the study subjects, and they divided into the control group and the research group according to the random number table method, 50 cases in each group. Both groups were treated with transcranial magnetic stimulation (TMS), and the study group was additionally treated with agomestatin. The self-rating anxiety scale (SAS), self-rating depression scale (SDS), Pittsburgh sleep quality index (PSQI), clinical efficacy and adverse reactions were compared between the two groups. Results After treatment, the SAS and SDS scores of the two groups were significantly decreased, and the control group was significantly higher than the study group, (P<0.05). After treatment, the PSQI scores of the two groups were significantly decreased, and the control group was significantly higher than the study group, (P<0.05). The total effective rate of the control group was 82.00%, which was significantly lower than that of the research group, which was 96.00%, (P<0.05). The adverse reaction rate of the control group was 8.00% compared with that of the study group, which was 4.00%, and the difference was not statistically significant (P>0.05). Conclusion Agomestatin in the treatment of perimenopausal syndrome complicated with anxiety and depression can significantly improve the clinical symptoms and sleep quality of patients, and improve the curative effect.
|